Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 4/20 | 1.00 |
| ▸ | JAK2 | O60674 | 9/20 | 0.77 |
| ▸ | JAK1 | P23458 | 9/20 | 0.72 |
| ▸ | JAK3 | P52333 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237675 | 0.92 | TYK2 (0.84) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL13031585 | 0.91 | TYK2 (0.83) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL13031226 | 0.88 | JAK2 (0.82) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL2236851 | 0.87 | JAK2 (1.00) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL2239253 | 0.86 | TYK2 (1.00) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL2236966 | 0.85 | TYK2 (0.75) | TYK2JAK2JAK1 | |
| SCHEMBL13031243 | 0.84 | JAK1 (0.80) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL2242721 | 0.84 | JAK1 (1.00) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL2239774 | 0.84 | TYK2 (1.00) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL13031640 | 0.83 | JAK2 (0.79) | TYK2JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2019-02-19 | — | — | US | claimed |
| US-9415037-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2016-08-16 | — | — | US | claimed |
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2015-06-04 | — | — | US | claimed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | claimed |
| EP-2361251-B1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-04-30 | — | — | EP | claimed |
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-20170035738-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2017-02-09 | — | — | US | disclosed |
| US-20170035738-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2017-02-09 | — | — | US | disclosed |
| US-20170035738-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2017-02-09 | — | — | US | disclosed |
| US-9415037-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2016-08-16 | — | — | US | disclosed |
| US-9415037-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2016-08-16 | — | — | US | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-2361251-B1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-04-30 | — | — | EP | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| US-20100291151-A1 | 1-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TLR6, TRAF6, BMP6 | TYK2 191/4885JAK2 242/4885JAK1 100/4885 |
| US-20100291151-A1 | 1-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR | TACR1, HTR3A, HTR3C | TYK2 4791/4885JAK2 2588/4885JAK1 2767/4885 |
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | TRAF6, TLR6, IL6 | TYK2 234/4885JAK2 222/4885JAK1 115/4885 |
| US-20170035738-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TLR6, TRAF6, BMP6 | TYK2 191/4885JAK2 242/4885JAK1 100/4885 |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TRAF6, IL6, TLR6 | TYK2 171/4885JAK2 174/4885JAK1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.